文献速递青光眼

地高辛通过抑制铁死亡减轻高眼压并保护小梁网细胞

Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition.
PubMed 文献 · Invest Ophthalmol Vis Sci · 2026-01-01

本研究通过孟德尔随机化发现血清铁升高与原发性开角型青光眼(POAG)风险存在因果关联,POAG患者房水中铁和MDA升高、GPX4和GSH降低。整合小梁网表达谱与铁死亡基因集识别出SLC2A3、SCD、HBA1为核心基因,CMap筛选和分子对接提示地高辛为潜在治疗药物。地高辛可减轻H2O2诱导的HTMCs铁死亡,并在慢性高眼压大鼠模型中降低眼压。

要点

  • 血清铁升高与POAG风险存在因果关联,POAG房水呈铁死亡相关指标改变。
  • SLC2A3、SCD、HBA1被识别为连接铁死亡与小梁网损伤的核心基因。
  • 地高辛局部滴眼可减轻铁死亡并在COH大鼠中降低眼压。

核心结论

  • 地高辛通过抑制铁死亡并经SLC2A3/SCD/HBA1通路降低眼压,被认为是POAG的潜在治疗药物。

研究设计与样本

  • 对东亚全基因组关联研究数据进行孟德尔随机化分析,评估血金属与POAG的因果关系。
  • 用ELISA检测POAG患者房水中铁离子、MDA、GPX4、GSH。
  • 整合POAG患者小梁网全基因组表达与FerrDb铁死亡基因集识别核心调控基因。
  • 采用CMap数据库和分子对接筛选治疗化合物,并在H2O2诱导的小梁网铁死亡模型中验证。
  • 将地高辛制成局部滴眼液每日两次给予慢性高眼压(COH)大鼠模型评估降眼压疗效。

主要发现

  • 孟德尔随机化分析显示血清铁水平升高因果性增加POAG风险。
  • POAG患者铁和MDA水平升高,GPX4和GSH降低。
  • 识别出14个铁死亡相关差异表达基因,PPI分析确定SLC2A3、SCD、HBA1为连接铁死亡与小梁网损伤的核心基因。
  • 上述核心基因失调放大脂质过氧化级联反应。
  • 地高辛通过降低MDA和恢复GPX4显著减轻H2O2诱导的HTMCs铁死亡,并降低COH眼眼压。

关键数值与推荐

  • 孟德尔随机化分析显示血清铁水平升高因果性增加POAG风险。
  • POAG患者房水中铁和MDA升高、GPX4和GSH降低。
  • 识别出14个铁死亡相关差异表达基因,核心基因为SLC2A3、SCD、HBA1。
  • 地高辛局部滴眼每日两次降低COH大鼠眼压。

临床怎么用

  • 地高辛作为局部滴眼制剂在COH大鼠中显示降眼压效果,提示其可能用于POAG治疗。
  • 铁死亡相关指标(铁、MDA、GPX4、GSH)和核心基因SLC2A3/SCD/HBA1可能作为POAG机制相关标志物。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Emerging evidence implicates ferroptosis in trabecular meshwork (TM) injury during glaucoma pathogenesis. This study aims to systematically characterize ferroptosis-related gene signatures in primary open-angle glaucoma (POAG) and identify small-molecule therapeutics targeting this mechanism. METHODS: We performed Mendelian randomization (MR) analysis of East Asian genome-wide association study data to assess causal relationships between blood metals and POAG. Ferroptosis-related indicators (iron ions, MDA, GPX4, GSH) were measured in aqueous humor samples from patients with POAG using ELISA. Genome-wide expression of TM from patients with POAG was integrated with ferroptosis-related gene sets (FerrDb) to identify core regulatory genes. The CMap database and molecular docking were employed to screen therapeutic compounds, with subsequent validation in hydrogen peroxide (H2O2)-induced TM ferroptosis models. Digoxin was formulated as topical ophthalmic drops and administered twice daily to chronic ocular hypertension (COH) rat models to evaluate its IOP-lowering efficacy. RESULTS: MR analysis revealed that elevated serum iron levels causally increase POAG risk. Patients with POAG exhibited increased iron and MDA levels alongside decreased GPX4 and GSH. We identified 14 ferroptosis-related differentially expressed genes, with PPI analysis pinpointing SLC2A3, SCD, and HBA1 as hub genes linking ferroptosis to TM injury. Their dysregulation amplified lipid peroxidation cascades. CMap screening and molecular docking suggested ATPase inhibitor digoxin as a potential POAG therapeutic. Digoxin significantly attenuated H2O2-induced ferroptosis in HTMCs by reducing MDA and restoring GPX4, ultimately lowering IOP in COH eyes. CONCLUSIONS: Our findings establish digoxin as a promising therapeutic agent that suppresses ferroptosis and reduces IOP via the SLC2A3/SCD/HBA1 pathway, providing a transformative strategy for POAG treatment.

来源:Invest Ophthalmol Vis Sci,查看原文。版权归原作者所有。

引用

  1. Zhou X, Li Z, Zhang X, et al. Digoxin Attenuates Ocular Hypertension and Protects Trabecular Meshwork Cells via Ferroptosis Inhibition. Invest Ophthalmol Vis Sci. 2026. PMID: 41563015. doi:10.1167/iovs.67.1.46

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。